A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
By
Su-Jun Deng,
Xiaodan cao,
Chunyin Gu,
Zongda Wang,
Peipei Liu,
Xiaowu Liu,
Li Gao,
Fangfang Jia,
Li Yu,
Nan Li,
Guoping Jiang,
Jianjian Zhang,
Lu Yang,
Meng Shi,
Tianquan Hou,
Yanan Li,
Weichen Liang,
Guoqiao Lu,
Congyi Yang,
Yuting Wang,
Kaiwen Xia,
Zheng Xiao,
Jianhua Xue,
Xueyi Huang,
Xin Chen,
Zhongzong Pan,
Xueping Wang,
Haibing Guo,
Hong Liang,
Yanfeng Yao,
Ge Gao,
Yun Peng,
Xue Hu,
Juan Min,
Yiwu Zhou,
Kunpeng Liu,
Weiwei Guo,
Zhiming Yuan,
Donglin Song,
Wuxiang Guan,
Haixia Ma,
Xiao Hu,
Yecheng Zhang,
Zhen Chen,
Chao Shan
Posted 07 Feb 2021
bioRxiv DOI: 10.1101/2021.02.07.429299
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS- CoV-2 variants and result in more efficient control of the COVID-19 pandemic.
Download data
- Downloaded 407 times
- Download rankings, all-time:
- Site-wide: 71,127
- In microbiology: 4,765
- Year to date:
- Site-wide: 7,962
- Since beginning of last month:
- Site-wide: 11,834
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!